Companies › SamA Pharmaceutical
1 active drug program in 1 registered trial: 1 Phase 4; Respiratory; next expected readout Jul 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Atock Dry Syrup Unclear - proprietary combination formulation | – | Phase 4 | Acute Bronchitis | Jul 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06411925 | Atock Dry Syrup | Phase 4 | Acute Bronchitis | Respiratory | Jul 2027 |
No annotated target.
–
Aerogen Pharma ONY Kringle Pharma Bellus Health Inc. - a GSK company Meribank Biotech
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.